drugset / Trial / NCT00417209
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.
Timeline
- Start
- 2006-12
- Primary completion
- 2009-07
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | Oral |
| Comparator | fluorouracil | Small molecule | — | Intravenous |
| Subject | larotaxel | Small molecule | — | Intravenous |